scholarly journals Molecular Epidemiology Of Clinical Isolates Of Carbapenem Resistant Acinetobacter spp.

2017 ◽  
Author(s):  
Murat Telli ◽  
Mete Eyigör ◽  
Berna Korkmazgil ◽  
Neriman Aydın ◽  
Mustafa Altay Atalay
Keyword(s):  
Molecular Epidemiology ◽  
Clinical Isolates ◽  
Carbapenem Resistant ◽  
Acinetobacter Spp

scholarly journals A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 577
Author(s):  
Fernando Pasteran ◽  
Jose Cedano ◽  
Michelle Baez ◽  
Ezequiel Albornoz ◽  
Melina Rapoport ◽  
...  
Keyword(s):  
Acinetobacter Baumannii ◽  
Target Genes ◽  
Susceptibility Testing ◽  
Clinical Isolates ◽  
Drug Resistant ◽  
Carbapenem Resistant ◽  
Acinetobacter Spp

An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/relebactam combination were tested against 187 multi-drug resistant (MDR) Acinetobacter clinical isolates; both sulbactam/avibactam and sulbactam/relebactam restored sulbactam activity. A decrease ≥2 dilutions in sulbactam MICs was observed in 89% of the isolates when tested in combination with avibactam. Sulbactam/relebactam was able to restore sulbactam susceptibility in 40% of the isolates. In addition, the susceptibility testing using twenty-three A. baumannii AB5075 knockout strains revealed potential sulbactam and/or sulbactam/avibactam target genes. We observed that diazabicyclooctanes (DBOs) β-lactamase inhibitors combined with sulbactam restore sulbactam susceptibility against carbapenem-resistant Acinetobacter clinical isolates. However, relebactam was not as effective as avibactam when combined with sulbactam. Exploring novel combinations may offer new options to treat Acinetobacter spp. infections, especially for widespread oxacillinases and metallo-β-lactamases (MBLs) producers.

scholarly journals SUSCEPTIBILITY PATTERN OF CARBAPENEM-RESISTANT CLINICAL ISOLATES OF ACINETOBACTER SPP.

2016 ◽  
pp. 86-91
Author(s):  
Vukica Pantović ◽  
◽  
Marina Dinić ◽  
Dobrila Stanković Đorđević ◽  
Branislava Kocić ◽  
...  
Keyword(s):  
Clinical Isolates ◽  
Susceptibility Pattern ◽  
Carbapenem Resistant ◽  
Acinetobacter Spp

scholarly journals 1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S416-S416 ◽  
Author(s):  
Rusudan Okujava ◽  
Fernando Garcia-Alcalde ◽  
Andreas Haldimann ◽  
Claudia Zampaloni ◽  
Ian Morrissey ◽  
...  
Keyword(s):  
Standard Of Care ◽  
The United States ◽  
Multidrug Resistant ◽  
Clinical Isolates ◽  
First Year ◽  
Pseudomonas Spp ◽  
Carbapenem Resistant ◽  
Acinetobacter Spp ◽  
Carbapenem Resistant Enterobacteriaceae

Abstract Background Nacubactam (NAC, OP0595, RG6080) is a novel member of the diazabicyclooctane inhibitor family with a dual mode of action, acting as a β-lactamase inhibitor and an antibacterial agent by means of PBP2 inactivation. NAC restores and extends the activity of β-lactam antibiotics, such as meropenem (MEM), when used in combination against a variety of carbapenem-resistant Enterobacteriaceae (CRE). The first year results of the ROSCO surveillance study for MEM/NAC against contemporary clinical isolates are presented here. Methods Isolates (n = 4,695) collected in 2017 from 50 sites in the United States and European hospitals included 30 different species of Enterobacteriaceae (EB, n = 3,306), Pseudomonas spp. (n = 960) and Acinetobacter spp. (n = 429). The predominant species of EB are shown in figure below. MICs were determined by broth microdilution following CLSI methodology for MEM/NAC at a fixed 1:1 ratio (w:w) and by titrating MEM with a constant concentration of NAC at 4 mg/L. Results were compared with MIC values of MEM and NAC alone and standard of care antibiotics, including ceftazidime/avibactam (CAZ/AVI). Results MIC50/90 for MEM, NAC, and MEM/NAC against all EB isolates and by species are shown in the figure below. NAC alone displayed a bimodal MIC distribution for EB, with a prominent separation at ≤4 mg/L. MEM/NAC 1:1 inhibited 99.5, 99.7, and 99.9% of the 3,306 EB isolates tested, at ≤2, ≤4, and ≤8 mg/L, respectively; while MEM inhibited 96.5, 96.8, and 97.3% of the isolates at the same concentrations. Of 117 (3.5% of total EB) MEM nonsusceptible (by EUCAST) and multidrug resistant (MDR, by Magiorakos AP, et al., 2012) EB, 87.2, 92.3, and 96.6% were inhibited by MEM/NAC 1:1 at ≤2, ≤4, and ≤8 mg/L, respectively. Additionally, MEM/NAC1:1 displayed MIC ≤8 mg/L for 33 out of 37 CAZ/AVI-resistant MDR EB isolates. MEM/NAC had a similar activity to MEM alone against Pseudomonas spp. and Acinetobacter spp. Conclusion MEM/NAC combination shows excellent in vitro activity against current clinical EB isolates and the potential to extend MEM activity to MDR, MEM nonsusceptible and CAZ/AVI-resistant isolates, which supports the continued clinical development of MEM/NAC for infections caused by CREs. This project has been funded in part under HHS BARDA Contract HHSO100201600038C. Disclosures R. Okujava, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. F. Garcia-Alcalde, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. A. Haldimann, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. C. Zampaloni, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. I. Morrissey, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. S. Magnet, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. N. Kothari, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. I. Harding, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to Micron. K. Bradley, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary.

Coexistence of Metallo Beta Lactamase Resistant Gene Variants Among Clinical Isolates in Tertiary Care Hospital

2021 ◽  
Vol 18 (4) ◽  
pp. 429-436
Author(s):  
Santhiya K. ◽  
Jayanthi S. ◽  
Ananthasubramanian M. ◽  
Appalaraju B.
Keyword(s):  
Care Center ◽  
Tertiary Care ◽  
Medical Science ◽  
Geographical Location ◽  
Carbapenem Resistance ◽  
Clinical Isolates ◽  
Care Hospital ◽  
Detection Rates ◽  
Carbapenem Resistant ◽  
Global Threat

Background: Carbapenem-resistant Enterobacteriaceae (CRE) has emerged as a global threat with mortality risk ranging from 48%-71% worldwide. The emergence of MBL resistance is threatening as carbapenem is one of the last line antibiotics. A total 24 variants of NDM resistance raises a concern to the clinicians and epidemiologists worldwide. Objective: The study aims at identifying MBL resistance (NDM, IMP, VIM, GIM, SPM, and SIM) and its coexistence in clinical isolates in a single tertiary care center. Methodology: Forty five clinical isolates characterized phenotypically for Carbapenem resistance obtained from PSG Institute of Medical Science and Research (PSG IMSR), Coimbatore, between February to March 2018 were taken for analysis. Result: Out of the 45 Clinical isolates, 38 isolates (84%) were detected as MBL carriers. VIM, NDM, GIM, and SPM were the predominant resistance genes, with detection rates of 48.8%, 28.8%, 24.4%, and 22.2% respectively. Fifteen isolates were observed to harbor more than one MBL gene in coexistence. Two isolates - U42 and R714 (K. pneumoniae) were found to harbor all 5 MBL variants in combination. Conclusion: 33% of clinical isolates harboring multiple MBL variants is a concern in clinical settings. The presence of SPM and GIM gene amongst isolates in this geographical location within India is an indicator demanding continuous monitoring of these resistance determinants.

Sign in / Sign up

Export Citation Format

Share Document